cpx-351
Showing 1 - 25 of 30
Myeloid Tumor Trial in Memphis (CPX-351, MHA)
Recruiting
- Myeloid Neoplasm
- CPX-351
- MHA
-
Memphis, TennesseeSt. Jude Children's Research Hospital
Jan 20, 2023
Lymphoid Leukemia, Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Tampa (CPX-351)
Active, not recruiting
- Lymphoid Leukemia
- +3 more
- CPX-351
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Dec 30, 2022
Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes Trial in La Jolla,
Recruiting
- Acute Myelogenous Leukemia (AML) Due to Therapy
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Glasdegib
- CPX-351
-
Orange, California
- +2 more
Nov 30, 2022
Acute Myeloid Leukemia Trial in United States (CPX-351, Venetoclax, Midostaurin)
Active, not recruiting
- Acute Myeloid Leukemia
- CPX-351
- +3 more
-
Duarte, California
- +9 more
Jan 3, 2023
Acute Myeloid Leukemia (AML) in Remission Trial in Washington (CPX-351)
Recruiting
- Acute Myeloid Leukemia (AML) in Remission
- CPX-351
-
Washington, District of ColumbiaGeorgetown Lombardi Comprehensive Cancer Center
May 3, 2022
Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)
MDS Trial in Tampa, Saint Louis, Seattle (CPX-351, Research skin biopsy, Research blood draw)
Active, not recruiting
- Myelodysplastic Syndromes
- CPX-351
- +3 more
-
Tampa, Florida
- +2 more
Apr 1, 2022
Acute Myeloid Leukemia, Myelodysplastic Tumor Trial (Magrolimab, 7+3, CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myelodysplastic Neoplasm
- Magrolimab
- +2 more
- (no location specified)
Apr 24, 2023
Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, MDS Trial in Cleveland (CPX-351)
Recruiting
- Refractory Acute Myeloid Leukemia
- +2 more
- CPX-351
-
Cleveland, OhioCleveland Clinic, Case Comprehensive Cancer Center
Mar 15, 2022
Acute Myeloid Leukemia Trial in Miami (CPX-351, Midostaurin, Busulfan)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- +5 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health of South Florida
Jul 27, 2022
MDS Trial in New Haven (CPX-351)
Withdrawn
- MDS
- CPX-351
-
New Haven, ConnecticutYale University; Smilow Cancer Center
Jan 6, 2022
Leukemia, Myeloid, Acute Trial in New York (CPX-351)
Active, not recruiting
- Leukemia, Myeloid, Acute
- CPX-351
-
New York, New YorkWeill Cornell Medical College
Dec 10, 2021
MDS, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid Trial in New York (CPX-351, Fludarabine, Melphalan)
Active, not recruiting
- Myelodysplastic Syndromes
- +3 more
- CPX-351
- +4 more
-
New York, New YorkWeill Cornell Medical College
Jan 26, 2022
Acute Myeloid Leukemia Trial in New York (CPX-351, Gemtuzumab Ozogamicin)
Recruiting
- Acute Myeloid Leukemia
- CPX-351
- Gemtuzumab Ozogamicin
-
New York, New YorkWeill Cornell Medical College
Dec 21, 2021
Myelodysplastic Syndrome (MDS) Trial in Cleveland (CPX-351)
Recruiting
- Myelodysplastic Syndrome (MDS)
- CPX-351
-
Cleveland, OhioCleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
Apr 21, 2021
Acute Myeloid Leukemia, Myeloproliferative Syndrome Trial in France (CPX-351)
Not yet recruiting
- Acute Myeloid Leukemia
- Myeloproliferative Syndrome
- CPX-351
-
Amiens, France
- +33 more
Feb 7, 2022
Hematologic Malignancy, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia Trial in Canada, United States (CPX-351)
Completed
- Hematologic Malignancy
- +4 more
- CPX-351
-
Washington, District of Columbia
- +12 more
Jul 20, 2021
MDS, AML Trial in Austria, Germany (CPX-351, Daunorubicin, Cytarabine)
Recruiting
- MDS
- AML
- CPX-351
- +3 more
-
Linz, Austria
- +26 more
Sep 9, 2022
Newly Diagnosed Secondary or High Risk AML Trial in Spain (CPX-351)
Active, not recruiting
- Newly Diagnosed Secondary or High Risk AML
- CPX-351
-
Badalona, Spain
- +11 more
Jul 9, 2021
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Burkitt Lymphoma Trial in Cincinnati (CPX-351)
Completed
- Acute Myeloid Leukemia
- +7 more
- CPX-351
-
Cincinnati, OhioCincinnati Children's Hospital Medical Center
Nov 6, 2020
High Risk Acute Myeloid Leukemia Trial in Canada, United States (CPX-351, 7+3 (cytarabine and daunorubicin))
Completed
- High Risk Acute Myeloid Leukemia
- CPX-351
- 7+3 (cytarabine and daunorubicin)
-
Birmingham, Alabama
- +42 more
Jul 28, 2020
A Post-Marketing Observational Study of VYXEOS™
Completed
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
- Therapy-Related Acute Myeloid Leukemia
- CPX-351
-
Indianapolis, Indiana
- +6 more
Aug 4, 2020
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS) Trial in United States
Withdrawn
- Acute Myeloid Leukemia (AML)
- +2 more
- CPX-351
-
Los Angeles, California
- +4 more
Mar 12, 2018